Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients

被引：0
|
作者：
Zhang, L. [1 ]
Lu, S. [2 ]
Dechaphunkul, A. [3 ]
Chessari, S. [4 ]
Lanzarotti, C. [5 ]
Jordan, K. [6 ]
Aapro, M. [7 ]
机构：
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Prince Songkla Univ, Div Med Oncol, Hat Yai, Thailand
[4] Helsinn Healthcare, Corp Clin Dev, Lugano, Switzerland
[5] Helsinn Healthcare, Stat & Data Management, Lugano, Switzerland
[6] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[7] Clin Genolier, Multidisciplinary Oncol Inst, Ctr Canc, Genolier, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Jonas Nilsson
    Vittoria Piovesana
    Marco Turini
    Claudio Lezzi
    Jennifer Eriksson
    Matti Aapro
    Supportive Care in Cancer, 2022, 30 : 9307 - 9315
  • [42] Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.
    Celio, Luigi
    Bonizzoni, Erminio
    Bria, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study
    Schilling, Joerg
    Busch, Steffi
    Stefek, Andrea
    Muller, Eberhard
    Schwickerath, Juergen
    Altmann, Falk
    Hollander, Martin
    Karthaus, Meinolf
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Lee Schwartzberg
    Sally Y. Barbour
    Gary R. Morrow
    Gianluca Ballinari
    Michael D. Thorn
    David Cox
    Supportive Care in Cancer, 2014, 22 : 469 - 477
  • [45] Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Schwartzberg, Lee
    Barbour, Sally Y.
    Morrow, Gary R.
    Ballinari, Gianluca
    Thorn, Michael D.
    Cox, David
    SUPPORTIVE CARE IN CANCER, 2014, 22 (02) : 469 - 477
  • [46] Effectiveness of NEPA, an oral fixed-dose combination of NEtupitant and PAlonosetron in the prevention of chemotherapy-induced nausea-vomiting in patient receiving highly emetogenic chemotherapy regimens.
    Jadhav, Amit Y.
    Gupta, Sudeep
    Biswas, Ghanashyam
    Chandrakanth, M., V
    Dattatreya, Palanki Satya
    Thomas, Boben
    Gupta, Sumant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Barkate, Hanmant B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Efficacy of an intravenous formulation of NEPA, a fixed combination of fosnetupitant and palonosetron, compared with oral NEPA studies in the prevention of chemotherapy-induced nausea and vomiting (CINV): An analysis of 1026 patient experiences.
    Roeland, Eric
    Hesketh, Paul Joseph
    Zhang, Li
    Gralla, Richard J.
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Improved control of nausea and vomiting (CINV) with a fixed-dose combination of netupitant and palonosetron (NEPA) following highly emetogenic chemotherapy (HEC): Results from a pivotal study
    Gralla, R.
    Rossi, G.
    Rizzi, G.
    Palmas, M.
    Alyasova, A.
    Drobner, I.
    Hesketh, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S267 - S267
  • [49] Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
    Hesketh, P. J.
    Rossi, G.
    Rizzi, G.
    Palmas, M.
    Alyasova, A.
    Bondarenko, I.
    Lisyanskaya, A.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1340 - 1346
  • [50] Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients
    Agre, Suhas
    Agre, Madhura
    Pol, Pooja
    Tonse, Mubarakunnisa
    Mohanty, Mitasha
    Shaikh, Alfiya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
12345